Filing Flows › Ensysce Biosciences (ENSC) › Recalls, complaints & regulation
Ensysce Biosciences (ENSC): clinical trials
Ensysce Biosciences (ENSC) beyond its filings: 2 active clinical trials.
Ensysce Biosciences' latest quarter
Ensysce Biosciences, Q2 2026: revenue $1.2M (-15% year over year), operating margin -221.3%, net loss $2.6M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Ensysce Biosciences have?
2 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.